期刊名称：CANCER NANOTECHNOLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Aims and scope
Cancer is a group of diseases driven by inherently nanostructural problems (e.g. DNA issues). As such, there are obvious benefits to treatments employing nanoscale structures and processes. Additionally, as nanotechnologies are developing at a rapid rate, it is likely that many new themes will develop within the area in the next few years. With this in mind, Cancer Nanotechnology aims to provide a forum so that the most promising emerging themes should be pre-eminent in the minds of researchers working in one—or, indeed, both—of the disciplines of cancer research or nanotechnology.
Benefits of publishing with BMC
High visibility
Cancer Nanotechnology's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.
Speed of publication
Cancer Nanotechnology offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.
Flexibility
Online publication in Cancer Nanotechnology gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Cancer Nanotechnology are included in article alerts and regular email updates. Some may be highlighted on Cancer Nanotechnology’s pages and on the BMC homepage.
In addition, articles published in Cancer Nanotechnology may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Cancer Nanotechnology. A list of articles recently press-released by journals published by BMC is available here.
Copyright
As an author of an article published in Cancer Nanotechnology you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BMC license agreement).
For further information about the advantages of publishing in a journal from BMC, please click here.
Open access
All articles published by Cancer Nanotechnology are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
As authors of articles published in Cancer Nanotechnology you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BMC license agreement.
For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BMC can accommodate non-standard copyright lines. Please contact us if further information is needed.
Article-processing charges
Open access publishing is not without costs. Cancer Nanotechnology therefore levies an article-processing charge of £1060.00/$1570.00/€1290.00 for each article accepted for publication, plus VAT or local taxes where applicable.
If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.
BMC provides a free open access funding support service to help authors discover and apply for article processing charge funding. Visit our OA funding and policy support page to view our list of research funders and institutions that provide funding for APCs, and to learn more about our email support service.
Indexing services
The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BMC on SpringerLink.
We are working closely with relevant indexing services including PubMed Central and Web of Science (Clarivate Analytics) to ensure that articles published in Cancer Nanotechnology will be available in their databases when appropriate.
Instructions to Authors
Our 3-step submission process
-
Before you submit
Before you submit, we recommend familiarizing yourself with the following.
-
Ready to submit
To give your manuscript the best chance of publication, follow these editorial policies and formatting guidelines.
-
Submit and promote
After acceptance, we provide support so your article gains maximum impact in the scientific community and beyond.
Submit manuscript
Editorial Board
Editors-in-Chief
Steven Curley, Trinity Mother Frances Clinic, USA
Fred J. Currell, University of Manchester, UK
Sunil Krishnan, Mayo Clinic, USA
Associate Editor
Željka Krpetić, University of Salford, UK
Managing Editor
Mark Bellringer
Editorial Board
Sonia Antoranz Contera, Oxford University, UK
Raj Bawa, Rensselaer Polytechnic Institute, USA
Mathias Brust, University of Liverpool, UK
Esther Chang, Georgetown University Medical Center, USA
Wei Chen, University of Texas, USA
Paul K. Chu, City University of Hong Kong, Hong Kong
Jonathan Coulter, Queen's University Belfast, UK
Marco Durante, GSI Helmholtz Centre for Heavy Ion Research, Germany
Zahi Fayad, Mount Sinai School of Medicine, USA
Costas Hadjipanayis, Icahn School of Medicine at Mount Sinai, USA
Hossam Haick, Israel Institute of Technology, Israel
Hao Hong, University of Wisconsin USA
Joseph Irudayaraj, Purdue University, USA
Suneil Jain, Queen's University Belfast, UK
Jorge Kohanoff, Queen's University Belfast, UK
M.N.V. Ravi Kumar, Texas A&M University, USA
Sandrine Lacombe, University Paris-Sud, France
Chun Li, University of Texas, USA
Nigel Mason, The Open University, UK
Helen McCarthy, Queen's University Belfast, UK
Arben Merkoçi, Catalan Institute of Nanoscience and Nanotechnology, Spain
Samir Mitragotri, University of California Santa Barbara, USA
Jwa-Min Nam, Seoul National University, South Korea
Takuro Niidome, Kumamoto University, Japan
Adriele Prina-Mello, Trinity College Dublin, Ireland
Victor Puntes, Catalan Institute of Nanoscience and Technology, Spain
Jan Schuemann, Massachusetts General Hospital & Harvard Medical School, USA
Giuseppe Schettino, National Physical Laboratory, UK
Andrey Solov'yov, MBN Res. Center at Frankfurt Biotechnology Innovation Center, Germany
Suresh Valiyaveettil, National University of Singapore, Singapore
Thomas Webster, Northeastern University, USA
Volkmar Weissig, Midwestern University, USA
Younan Xia, Georgia Institute of Technology, USA
Xiu-Ping Yan, Nankai University, China
G.W. Yang, Sun Yat-sen University, China
Xian-Da Yang, Peking Union Medical College, China
|
